8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 16, 2013)

Filed April 16, 2013For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on April 16, 2013, to report its financial results for the first quarter ended March 31, 2013. The filing primarily serves to provide investors with the company's unaudited sales and earnings performance for the period. Key details are presented through an attached press release and supplementary financial data. This report is crucial for investors seeking to understand the company's recent operational and financial standing, including revenue generation and profitability trends in the initial quarter of 2013. While the 8-K itself is a notification of the release of financial information, the attached press release and supplementary data are where investors will find the substance of the results. These documents would typically detail sales figures across JNJ's various business segments (Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Health Care), earnings per share, net income, and potentially forward-looking guidance or commentary on market conditions. Investors should review the attached materials for a comprehensive understanding of JNJ's Q1 2013 performance and its implications for the rest of the fiscal year.

Key Highlights

  • 1Johnson & Johnson reported its first quarter 2013 financial results on April 16, 2013.
  • 2The report includes sales and earnings data for the quarter ended March 31, 2013.
  • 3An official press release dated April 16, 2013, accompanies the filing.
  • 4Unaudited comparative supplementary sales data and condensed consolidated statements of earnings are provided.
  • 5This 8-K filing serves as the official public disclosure mechanism for JNJ's Q1 2013 financial performance.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Johnson & Johnson's financial results, specifically sales and earnings, for the first quarter ended March 31, 2013, to the public and investors.

The detailed financial performance figures are contained within the attached press release (Exhibit 99.15) and the unaudited comparative supplementary sales data and condensed consolidated statement of earnings (Exhibit 99.2O) that accompany this 8-K filing.

Investors can expect to find key financial metrics such as net sales, earnings per share, net income, and potentially segment-specific sales performance within the attached press release and financial statements.

While the 8-K itself is an event-driven filing, the accompanying press release may contain commentary on future outlook or guidance from Johnson & Johnson's management, which investors should review.